Literature DB >> 14558866

Heart failure: how can we prevent the epidemic?

Duncan J Campbell1.   

Abstract

Heart failure prevalence is increasing because of the ageing of the population and the longer survival of people experiencing myocardial infarction and heart failure. The lifetime risk of developing heart failure in Western countries is about 20%. The increasing prevalence of overweight, obesity and diabetes is likely to accelerate heart failure incidence. While there have been major advances in treating heart failure, a preventive approach promises greater benefit to a larger proportion of the community. The medical strategy for heart failure prevention, based on calculation of individual risk, is focused on the minority of individuals who exceed an arbitrary risk threshold. A public health strategy targeting the whole population offers a greater prospect of reducing the incidence of heart failure and other cardiovascular disease. A multitiered approach, encompassing environmental determinants of lifestyle, legislation, and education about healthy lifestyles throughout life, in addition to aggressive control of risk factors in high-risk individuals, is likely to have the greatest impact.

Entities:  

Mesh:

Year:  2003        PMID: 14558866     DOI: 10.5694/j.1326-5377.2003.tb05620.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  8 in total

1.  Predictive medicine in urology.

Authors:  Bernd J Schmitz-Dräger; Nuria Malats; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-18       Impact factor: 4.226

2.  Association between left ventricular dysfunction, anemia, and chronic renal failure. Analysis of the Heart Failure Prevalence and Predictors in Turkey (HAPPY) cohort.

Authors:  A Kepez; B Mutlu; M Degertekin; C Erol
Journal:  Herz       Date:  2013-11-13       Impact factor: 1.443

Review 3.  The experience of living with chronic heart failure: a narrative review of qualitative studies.

Authors:  Yun-Hee Jeon; Stefan G Kraus; Tanisha Jowsey; Nicholas J Glasgow
Journal:  BMC Health Serv Res       Date:  2010-03-24       Impact factor: 2.655

4.  Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.

Authors:  Jacques LeLorier; Nugek S B Rawson
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

5.  Post-discharge medication reviews for patients with heart failure: a pilot study.

Authors:  Anne Ponniah; Sepehr Shakib; Christopher J Doecke; Merelyn Boyce; Manya Angley
Journal:  Pharm World Sci       Date:  2008-06-13

6.  Heart Failure Etiology Is Usually Pluricausal Whether or Not There is Associated Coronary Disease.

Authors:  Arthur L Klatsky; Sharon Gronningen; Natalia Udaltsova; Douglas Chartier; Somjot S Brar; James Schipper; Robert J Lundstrom
Journal:  Perm J       Date:  2007

Review 7.  Chronic heart failure: we are fighting the battle, but are we winning the war?

Authors:  John J Atherton
Journal:  Scientifica (Cairo)       Date:  2012-12-20

8.  Comparison of high-flow oxygen treatment and standard oxygen treatment in patients with hypertensive pulmonary edema.

Authors:  Kemal Şener; Mustafa Çalış; Zikret Köseoğlu; Sezai Sarı; Mustafa Polat; Durdu Mehmet Üzücek; Sadiye Yolcu
Journal:  Anatol J Cardiol       Date:  2020-10       Impact factor: 1.596

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.